Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05068609 · ClinicalTrials.gov registry record
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
A clinical trial of Squamous Cell Carcinoma of the Head and Neck, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 509
- Enrollment target
- 1
- Study location
NCT05068609 is a study of Squamous Cell Carcinoma of the Head and Neck that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 509 participants, above the 129-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (295% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05068609, a study of Squamous Cell Carcinoma of the Head and Neck, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 509 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among participants treated with nivolumab in a real-world setting.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
Study Locations (1)
New Jersey
- Local Institution - Mount Laurel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2020-08-13 |
| Est. Completion | 2021-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05068609
The ClinicalTrials.gov registry entry for NCT05068609 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 129-participant average among 29 other Squamous Cell Carcinoma of the Head and Neck trials with a reported enrollment target (295% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT05068609 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05068609 about?
NCT05068609 is a clinical study titled "A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)". The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among participants treated with nivolumab in a real-world setting.
What is the current status of trial NCT05068609?
This trial is currently completed. The enrollment target is 509 participants. The study started on 2020-08-13. Estimated completion is 2021-10-18.
What conditions does trial NCT05068609 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of the Head and Neck.
What interventions are being tested in trial NCT05068609?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05068609?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05068609 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of the Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
RECRUITING · Phase 2
-
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
RECRUITING · Phase 2
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
RECRUITING · Phase 1
-
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.